NUVB · Healthcare
NUVATION BIO INC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
44
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in NUVATION BIO INC? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$2.2B
Industry
Biotechnology
Sector
Healthcare
Exchange
NYSE
About NUVATION BIO INC
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Who's behind the signal
Every informed buyer we can see on NUVB, across all three feeds.
Hedge funds · 8
D.E. Shaw & Co
New position
Point72 (Steve Cohen)
New position
Gotham Asset Mgmt (Greenblatt)
Increased +83%
Icahn Enterprises (Icahn)
Unchanged
AQR Capital Management
Decreased −18%
Greenlight Capital (Einhorn)
Unchanged
+2 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
NUVATION BIO INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
2
New positions
1
Increasing
3
Decreasing
2
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+83%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.4×
% of portfolio
0.6%
Position change
—
0.6% of Icahn Enterprises's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−18%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
—
0.0% of Greenlight Capital's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−94%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−85%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to NUVATION BIO INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NUVATION BIO INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime